Broad Institute

JUNE 21, 2023

With further development, the findings could inform a potential treatment that lowers oxygen levels in certain tissues in humans to reverse advanced disease. The study appeared recently in Human Molecular Genetics. “If Mootha’s lab has been studying hypoxia as a potential treatment for rare neurological diseases since 2016.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections. A combined MD/PhD program offered both opportunities.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Drug Target Review

NOVEMBER 8, 2023

Cell therapies hold immense promise for revolutionising the treatment of some of the most challenging diseases, but several technological and logistical hurdles stand in the way of unlocking their full potential. By harnessing the fundamental biology of T cells, Senza5 can be used to improve the efficacy of almost any CAR-T therapy.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

Drug Target Review

AUGUST 29, 2024

MR : We started by focusing on T-cell lymphoma because it is an orphan disease with very limited effective therapies, but, importantly, we think that CD5 deletion enhances any type of CAR T cell treatment. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

JULY 1, 2024

As a non-NSAID, it reduces adverse effects associated with these pain relief drugs, including kidney injury, GI gastritis/ulceration and blood pressure elevation, which can affect patients with cardiovascular disease and the elderly. We set out to improve health by developing a novel non-opioid that avoids potential abuse.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Clinical Trials Engineering DNA 91

Drug Target Review

FEBRUARY 26, 2024

Her research focus is on epigenetic regulation of melanoma and other cancers as well as wound healing, ageing biology and the development of novel epigenetic therapies targeting cancers and skin diseases and she is the owner of 15 issued and pending patents relevant to her research. Dr Alani received her M.D.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59